The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...
as measured by the National Average Drug Acquisition Cost. This generated more than $7.3 billion in revenue. Furthermore, PBMs reimbursed their affiliated pharmacies at a higher rate than they ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
the affiliated pharmacies of the Big Three PBMs earned more than $7.3 billion in dispensing revenue above their estimated acquisition cost, as determined by the National Average Drug Acquisition ...
Type 2 diabetes drug Ozempic and COVID drug Paxlovid saw price hikes of about 3% each, according to 46brooklyn, which uses Elsevier wholesale acquisition cost data in its analysis ... 25 drugs in ...
which uses National Average Drug Acquisition Cost, or NADAC, data in its analysis. NPR reached out to the drugs' makers to ask them why they raised these prices. Neither detailed the specifics ...
Type 2 diabetes drug Ozempic and COVID drug Paxlovid saw price hikes of about 3% each, according to 46brooklyn, which uses Elsevier wholesale acquisition cost data in its analysis. NPR reached out ...